The Substituent Nitrogen Is An Amino Nitrogen Attached Indirectly To A Ring By Acyclic Nonionic Bonding Patents (Class 564/164)
-
Publication number: 20020040003Abstract: Disclosed are compounds of the Formula I 1Type: ApplicationFiled: July 5, 2001Publication date: April 4, 2002Inventors: Laurence E. Burgess, John J. Gaudino, Robert D. Groneberg, Mark H. Norman, Martha E. Rodriguez, Xicheng Sun, Eli M. Wallace
-
Patent number: 6362174Abstract: The present invention provides novel N-type calcium channel blockers, compositions comprising them, and methods of their use. The compounds of the invention are useful in the treatment of stroke, cerebral ischemia, pain, epilepsy, and head trauma.Type: GrantFiled: August 9, 2001Date of Patent: March 26, 2002Assignee: Warner-Lambert CompanyInventors: Michael Francis Rafferty, Yuntao Song
-
Publication number: 20020019568Abstract: The invention relates to a process for the enantioselective preparation of tolterodine and analogues and salts thereof comprises the steps of:Type: ApplicationFiled: July 31, 2001Publication date: February 14, 2002Inventors: Pher G. Andersson, Christian Hedberg
-
Patent number: 6344486Abstract: The present invention is directed to aminoguanidine and alkoxyguanidine compounds, including compounds of Formula I: wherein X is O or NH, L is —O— or —SO2—, and R1-R4, R9-R19, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing the compounds of Formula I. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal.Type: GrantFiled: April 1, 1999Date of Patent: February 5, 2002Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Richard M. Soll, Tianbao Lu, Bruce E. Tomczuk, Thomas P. Markotan, Colleen Siedem
-
Publication number: 20020013459Abstract: The present invention relates to processes for the preparation of macrocyclic molecules containing anti-succinate residues which inhibit metalloproteinases such as aggrecanase, and the production of tumor necrosis factor (TNF). The anti-succinates are formed by an Ireland Claisen rearrangement of a silyl ketene acetal which proceeds with high stereoselectivity.Type: ApplicationFiled: July 31, 2001Publication date: January 31, 2002Inventors: Roberta L. Dorow, Silvio Campagna, Pasquale N. Confalone, Fuqiang Jin, Zhe Wang
-
Publication number: 20010056207Abstract: Hydrated N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro benzamide hydrochloride characterized in that it:Type: ApplicationFiled: June 29, 2001Publication date: December 27, 2001Applicant: SmithKline Beecham p.l.c.Inventors: Graham Ralph Slater, Paul Jeffrey Westlake
-
Publication number: 20010056123Abstract: Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.Type: ApplicationFiled: December 8, 2000Publication date: December 27, 2001Applicant: AJINOMOTO CO., INCInventors: Tadakiyo Nakagawa, Kazuyuki Sagi, Kaoru Yoshida, Yumiko Fukuda, Masataka Shoji, Shunji Takehana, Takashi Kayahara, Akira Takahara
-
Publication number: 20010056119Abstract: The subject invention provides compounds which are easily metabolized by the metabolic drug detoxification systems. Particularly, fluvoxamine analogs which have been designed to include esters within the structure of the compounds are taught. Also provided are methods of treating depression and affective disorders, such as obsessive compulsive disorder. Pharmaceutical compositions of the fluvoxamine analogs are also taught.Type: ApplicationFiled: April 24, 2001Publication date: December 27, 2001Inventor: Pascal Druzgala
-
Publication number: 20010053851Abstract: Para-alkynyl phenyl heteroaromatic amides which are active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes.Type: ApplicationFiled: April 25, 2001Publication date: December 20, 2001Inventor: Paige E. Mahaney
-
Patent number: 6323202Abstract: The invention provides compounds of the formula 1 that are active against the HSV primase enzyme: wherein R1 is hydroxy or amino; R2 is hydrogen, halo, (C1-4)alkyl or (C1-4)alkoxy; R3 is hydrogen, halo, (C1-4)alkyl, (C1-4)alkoxy, amino or azido; R4 has the same significance as R2; R5 is hydrogen or (C1-4)alkyl; and R is (C1-7)alkyl, (C3-6)cycloalkyl, {phenyl(C1-7)alkyl}, {phenyl(C1-7)alkoxy}, {{(monocyclic heterocyclo)-{(C1-7)alkoxy}}, CH(W)C(O){O-(C1-4)alkyl} wherein W is hydrogen or (C1-7)alkyl, or wherein Y is hydrogen or (C1-7)alkyl, and Z is (C1-7)alkyl, (C3-6) cycloalkyl, {(C3-6)cycloalkyl}- {(C1-7)alkyl}, phenyl(C1-7)alkyl or {{(monocyclic heterocyclo)-{(C1-7)alkyl}}, or Y and Z together with the nitrogen atom to which they are attached represent, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl or 1-(4-methylpiperazinyl); with the provisos that (1) when R is CH(WType: GrantFiled: March 24, 2000Date of Patent: November 27, 2001Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Bruno Simoneau, Michele Liuzzi, Anton Mentrup
-
Patent number: 6319925Abstract: Oxime ethers of formula (I) in which a) X is an N atom and Y is an oxygen atom or NH, or b) X is CH and Y is an oxygen atom, in which furthermore R1 is C1-C4alkyl; R2 is hydrogen, C1-C4alkyl or cyclopropyl; and in which R3 and R4 are as defined herein, are fungicidal, acaricidal and insecticidal active ingredients for agriculture. They can be employed as formulated crop protection compositions.Type: GrantFiled: December 22, 1997Date of Patent: November 20, 2001Assignee: Bayer AktiengesellschaftInventor: Hugo Ziegler
-
Patent number: 6316440Abstract: The present invention provides novel N-type calcium channel blockers, compositions comprising them, and methods of their use. The compounds of the invention are useful in the treatment of stroke, cerebral ischemia, pain, epilepsy, and head trauma.Type: GrantFiled: December 27, 1999Date of Patent: November 13, 2001Assignee: Warner-Lambert CompanyInventors: Michael Francis Rafferty, Yuntao Song
-
Patent number: 6313173Abstract: The invention relates to novel glyoxylic acid amides, to a process for their preparation and to their use as pesticides.Type: GrantFiled: May 12, 1999Date of Patent: November 6, 2001Assignee: Bayer AktiengesellschaftInventors: Thomas Seitz, Klaus Stenzel
-
Patent number: 6313339Abstract: Certain cyclopropyl oxime ethers substituted by aryl and heterocyclic moieties possess broad spectrum fungicidal and insecticidal properties. These compounds are disclosed along with compositions containing these compounds and methods for controlling fungi and insects by the use of a fungitoxic or insecticidal amount of these compounds.Type: GrantFiled: February 17, 2000Date of Patent: November 6, 2001Inventors: Ronald Ross, Jr., Duyan Vuong Nguyen, Steve Howard Shaber
-
Patent number: 6313344Abstract: Compounds of formula (I), wherein either X is CH or N, Y is OR1 and Z is O, or X is N, Y is NHR8 and Z is O, S or S(═O); R1, R2 and R3 are as defined according to the specification; m is 0, 1 or 2; R5 is, for example, halogen, C1-C6alkyl, halo-C1-C6alkyl or C3-C6cycloalkyl; n is 0, 1, 2, 3 or 4; R9 is methyl, fluoromethyl or difluoromethyl; A and R7 are as defined according to the specification; D is O, S, —S(═O) or S(═O)2; G is C1-C6aalkylene; T—R6 is R6, —C(═N—O—A1—R77)—R6; —SiR14(R15)—R6; —C(═O)—R6; —C(R16)═C(R17)—R6, —C≡C—R6 or —D—R6; R6 is C1-C4alkyl or unsubstituted or substituted aryl or heteroaryl; A1 and R77 are as defined above for A and R7; L is U—R18, P(OR)vR11R12, P(S)wR11R12 or N(aryl)R13; v and w are 0 or 1; U—R18 is —C(═O)—C(═O)—R18; —C(OH)—C(OH)—R18; —C(═N&mdType: GrantFiled: May 27, 1998Date of Patent: November 6, 2001Assignee: Bayer AktiengesellschaftInventors: Stephan Trah, Henry Szczepanski, Ottmar Franz Hüter, Roger Graham Hall, Saleem Farooq, Alfons Pascual
-
Publication number: 20010037039Abstract: Aminoguanidine and alkoxyguanidine compounds, including compounds of the formula: 1Type: ApplicationFiled: March 16, 2001Publication date: November 1, 2001Applicant: 3-Dimensional Pharmaceuticals, Inc.Inventors: Bruce E. Tomczuk, Richard M. Soll, Tianbao Lu, Cynthia L. Fedde, Carl R. Illig, Thomas P. Markotan, Thomas P. Stagnaro
-
Patent number: 6306911Abstract: This invention relates to a series of substituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules that bind to neutral sphingomyelinase and inhibit its activity.Type: GrantFiled: February 7, 2000Date of Patent: October 23, 2001Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Michael P. Wachter, Praful Lalan
-
Patent number: 6306903Abstract: The present invention relates to novel and known alpha-aminoamide compounds, to a process for their preparation, to pharmaceutical composition containing them and to their use as therapeutic agents. In particular, the compounds of the present invention are endowed with analgesic properties and are particularly useful for the treatment and alleviation of chronic and neuropathic pain.Type: GrantFiled: August 29, 2000Date of Patent: October 23, 2001Assignee: Newron Pharmaceuticals S.p.A.Inventors: Paolo Pevarello, Mario Varasi, Patricia Salvati, Claes Post
-
Patent number: 6306871Abstract: A series of activated iodo-benzamide derivatives are described as antineoplastic and antiviral drug compounds. The compounds generally possess a chelating group, a thiol trapping group and an activating group. The presumptive mechanism of action in preventing cancer cell and virus replication is through inhibition of the binding of transcription factors to zinc finger binding domains. The compounds are effective in inhibiting growth of a variety of human and animal tumor and leukemia cell lines at low concentrations.Type: GrantFiled: September 19, 2000Date of Patent: October 23, 2001Inventors: Randall W. Yatscoff, Robert T. Foster, Selvaraj Naicker
-
Patent number: 6303819Abstract: Compounds which are substituted 2-benzylamino-2-phenyl-acetamide compounds of formula (I) wherein: n is zero, 1, 2 or 3; X is —O—, —S—, —CH2— or —NH—; each of R, R1, R2 and R3, independently, is hydrogen, C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy or trifluoromethyl; each of R4 and R5, independently, is hydrogen, C1-C6 alkyl or C3-C7 cycloalkyl; or pharmaceutically acceptable salts thereof, are useful in treating conditions such as chronic or neuropathic pain.Type: GrantFiled: September 11, 2000Date of Patent: October 16, 2001Assignee: Newron Pharmaceuticals S.p.A.Inventors: Paolo Pevarello, Mario Varasi, Patricia Salvati, Claes Post
-
Patent number: 6288071Abstract: Pesticidally active cyclohexadienyl derivative compounds of the formula I that are esters, oximes or amides are claimed. These compounds may be used as fungicides, acaricides and insecticides in plant protection.Type: GrantFiled: December 10, 1998Date of Patent: September 11, 2001Assignee: Bayer AktiengesellschaftInventors: Henry Szczepanski, Martin Zeller, Ottmar Franz Hüter
-
Patent number: 6284796Abstract: Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.Type: GrantFiled: January 25, 1999Date of Patent: September 4, 2001Assignee: Abbott LaboratoriesInventors: Andrew G. Geyer, William J. McClellan, Todd W. Rockway, Kent D. Stewart, Moshe Weitzberg, Michael D. Wendt
-
Patent number: 6274628Abstract: The present invention is directed to aminoguanidine and alkoxyguanidine compounds, including compounds of Formula I: wherein X is O or NH, L is —O— or —SO2—, and R1-R4, R9-R19, Ra, Rb, Rc, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing the compounds of Formula I. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal.Type: GrantFiled: April 1, 1999Date of Patent: August 14, 2001Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Richard M. Soll, Tianbao Lu, Bruce E. Tomczuk, Thomas P. Markotan, Colleen Siedem
-
Publication number: 20010008947Abstract: Use in the prevention and/or in the treatment of neurodegenerative diseases of 2-amino-4-phenyl-4-oxo-butyric acid derivatives which act as kynureninase enzyme inhibitors and/or kynurenine-3-hydroxylase enzyme inhibitors.Type: ApplicationFiled: October 14, 1997Publication date: July 19, 2001Inventors: MARIO VARASI, ANTONIO GIORDANI, CARMELA SPECIALE, MASSIMO CINI, ALBERTO BIANCHETTI
-
Patent number: 6258982Abstract: The present invention relates to a hydrogenation process for the preparation of aromatic amino compounds containing directly on the aryl ring or in a side chain one or more entities that may also undergo hydrogenation, such as carbon multiple bonds, nitrile groups, imino groups or carbonyl groups. The preparation is carried out by catalytic hydrogenation of the corresponding aromatic nitro compounds in the presence of a phosphorus-modified noble metal catalyst. The invention relates also to the use of modified noble metal catalysts for the hydrogenation of aromatic nitro compounds containing carbon multiple bonds and/or substituted by nitrile, imino or carbonyl groups.Type: GrantFiled: March 10, 1999Date of Patent: July 10, 2001Assignee: Novartis AGInventors: Peter Baumeister, Urs Siegrist, Martin Studer
-
Patent number: 6255285Abstract: The present invention has as its object providing phenethylamine derivatives that typically function as a motilin receptor antagonist and which are useful as medicines. The invention provides compounds represented by the general formula (1): (wherein A is typically an amino acid residue, R1 is typically R6—CO—, R2 is typically a hydrogen atom, R3 is typically —CO—R7, R4 is typically an alkyl group, R5 is typically a hydroxyl group, R6 is typically an alkyl group, and R7 is typically an amino group).Type: GrantFiled: February 15, 2000Date of Patent: July 3, 2001Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Ken-ichiro Kotake, Toshiro Kozono, Tsutomu Sato, Hisanori Takanashi
-
Patent number: 6251917Abstract: Compounds of the formula where R1, R2, R3, X and n are as defined in the description, are inhibitors of cysteine protease.Type: GrantFiled: May 26, 1999Date of Patent: June 26, 2001Assignee: BASF AktiengesellschaftInventors: Wilfried Lubisch, Achim Möller, Hans-Jörg Treiber
-
Patent number: 6225323Abstract: A series of activated iodo-benzamide derivatives are described as antineoplastic and antiviral drug compounds. The compounds generally possess a chelating group, a thiol trapping group and an activating group. The presumptive mechanism of action in preventing cancer cell and virus replication is through inhibition of the binding of transcription factors to zinc finger binding domains. The compounds are effective in inhibiting growth of a variety of human and animal tumor and leukemia cell lines at low concentrations.Type: GrantFiled: August 11, 1998Date of Patent: May 1, 2001Assignee: Joseph KoziakInventors: Randall W. Yatscoff, Robert T. Foster, Selvaraj Naicker
-
Patent number: 6218389Abstract: The invention provides compounds of formula as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases. Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.Type: GrantFiled: July 31, 1998Date of Patent: April 17, 2001Assignee: The Procter & Gamble Co.Inventors: Neil Gregory Almstead, Roger Gunnard Bookland, Yetunde Olabisi Taiwo, Rimma Sandler Bradley, Rodney Dean Bush, Biswanath De, Michael George Natchus, Stanislaw Pikul
-
Patent number: 6191165Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 30, 1997Date of Patent: February 20, 2001Assignee: Allelix Neuroscience Inc.Inventors: Vassil Iliya Ognyanov, Laurence A. Borden, Stanley Charles Bell, Jing Zhang
-
Patent number: 6187812Abstract: Phenylacetic acid derivatives of the formula I where the substituents and the index have the following meanings: X is oxygen or sulfur; R is hydrogen or alkyl; R1 is hydrogen or alkyl; R2 is cyano, nitro, trifluoromethyl, halogen, alkyl or alkoxy; m is 0, 1 or 2, it being possible for the R2 radicals to be different if m is 2; R3 is hydrogen, cyano, nitro, hydroxyl, amino, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, alkylamino or dialkylamino; R4 is hydrogen, cyano, nitro, hydroxyl, amino, halogen, unsubstituted or substituted alkyl, alkoxy, alkylthio, alkylamino, dialkylamino, alkenyl, alkenyloxy, alkenylthio, alkenylamino, N-alkenyl-N-alkylamino, alkynyl, alkynyloxy, alkynylthio, alkynylamino, N-alkynyl-N-alkylamino; unsubstituted or substituted cycloalkyl, cycloalkoxy, cycloalkylthio, cycloalkylamino, N-cycloalkyl-N-alkylamino, cycloalkenyl, cycloalkenyloxy, cycloalkenylthio, cycloalkenylamino, N-cycloalkenyl-N-alkylamino, heterocyclyl, heterocyclyloxy, heterocyclyType: GrantFiled: February 3, 2000Date of Patent: February 13, 2001Assignee: BASF AktiengesellschaftInventors: Herbert Bayer, Hubert Sauter, Ruth Müller, Wassilios Grammenos, Albrecht Harreus, Reinhard Kirstgen, Franz Röhl, Eberhard Ammermann, Gisela Lorenz
-
Patent number: 6177463Abstract: The invention relates to new oxime derivatives, to a plurality of processes for their preparation, and to their use as pesticides.Type: GrantFiled: September 3, 1996Date of Patent: January 23, 2001Assignee: Bayer AktiengesellschaftInventors: Peter Gerdes, Herbert Gayer, Bernd-Wieland Kr{umlaut over (u)}ger, Bernd Gallenkamp, Heinz-Wilhelm Dehne, Stefan Dutzmann, Gerd H{umlaut over (a)}nssler, Klaus Stenzel
-
Patent number: 6177462Abstract: Compounds with fungicidal and insecticidal properties having formula wherein X is N or CH; Y is O, S or NR6; A is independently hydrogen, halo, cyano, (C1-C12)alkyl, or (C1-C12)alkoxy; R1 and R6 is independently hydrogen or (C1-C4)alkyl; R2 is independently hydrogen, (C1-C12)alkyl, halo(C1-C12)alkyl, (C3-C7)cycloalkyl, (C2-C8)alkenyl, halo(C2-C8)alkenyl, (C2-C8)alkynyl, halo(C2-C8)alkynyl, aryl, aralkyl, heterocyclic, or heterocyclic(C1-C4)alkyl; R3 is independently hydrogen or (C1-C4)alkyl; R4 and R5 is independently hydrogen, (C1-C4)alkyl, aryl, aralkyl, aryl(C2-C8)alkenyl, aryl(C2-C8)alkynyl, heterocyclic, or heterocyclic(C1-C4)alkyl wherein if one of R4 and R5 is hydrogen or (C1-C4)alkyl than the other of R4 and R5 is other than hydrogen or (C1-C4)alkyl, and its enantiomers and stereoisomers and agronomically acceptable salts.Type: GrantFiled: January 26, 1999Date of Patent: January 23, 2001Assignee: Rohm and Haas CompanyInventors: Zhang Lixin, Li Zongcheng, Li Zhinian, Zhang Hong, Liu Changling, Li Bin, Steven Howard Shaber
-
Patent number: 6169116Abstract: Compounds of formula I wherein R1, R2, R3, R4 and R5 are as defined in the description, are useful as pharmaceuticals.Type: GrantFiled: June 28, 1999Date of Patent: January 2, 2001Assignee: Novartis AGInventor: Robert Swoboda
-
Patent number: 6156923Abstract: The invention relates to a process for the preparation of compounds of the formula ##STR1## or, if appropriate, a tautomer thereof, in each case in the free form or in salt form, in whichA, X, Y, Z, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7, R.sub.9 and n are as defined in claim 1 and the C.dbd.N double bond marked with E has the E configuration, which comprisesa1) reacting either a compound of the formula (II) mentioned above with a compound of the formula (III) mentioned above, in which X.sub.1 is a leaving group, ora2) a compound of the formula (IV) mentioned above, if appropriate in the presence of a base, with a compound of the formula (V) mentioned above, orb1) reacting a compound of the formula (VI) mentioned above with a compound of the formula R.sub.7 --A--X.sub.2 (VII), in which X.sub.Type: GrantFiled: December 6, 1996Date of Patent: December 5, 2000Assignee: Novartis CorporationInventors: Saleem Farooq, Stephan Trah, Hugo Ziegler, Rene Zurfluh
-
Patent number: 6150386Abstract: Compounds of formula (I) and their possible isomers and isomer mixtures, in which (Z) is a group (a), (b), (c) or (d) and in which the other substituents are as defined herein.Type: GrantFiled: December 22, 1997Date of Patent: November 21, 2000Assignee: Novartis Crop Protection, Inc.Inventors: Stephan Trah, Rene Zurfluh
-
Patent number: 6150374Abstract: The invention relates to novel substituted cycloalkenes of the formula (I), ##STR1## to a plurality of processes for their preparation, and to novel intermediates and a plurality of processes for their preparation.Type: GrantFiled: September 29, 1997Date of Patent: November 21, 2000Assignee: Bayer AktiengesellschaftInventors: Herbert Gayer, Peter Gerdes, Ralf Tiemann, Stefan Dutzmann, Klaus Stenzel
-
Patent number: 6147224Abstract: Compounds of Formula 1, Formula 2 or Formula 3 where X is O, S, or (CR.sub.1 R.sub.1).sub.n where n is 0, 1 or 2; Y is a bivalent radical having Formula 4 or Formula 5 where o is an integer from 1 to 4 ##STR1## or Y is a bivalent aryl or 5 or 6 membered heteroaryl radical having 1 to 3 heteroatoms selected from N, S and O, said aryl or heteroaryl groups being unsubstituted, or substituted with 1 to 3 C.sub.1-6 alkyl or with 1 to 3 C.sub.1-6 fluoroalkyl groups; and the remaining symbols have the meaning described in the specification, have RXR selective retinoid agonist-like activity.Type: GrantFiled: October 1, 1998Date of Patent: November 14, 2000Assignee: Allergan Sales, Inc.Inventors: Vidyasagar Vuligonda, Kwok Yin Tsang, Jayasree Vasudevan, Roshantha A. Chandraratna
-
Patent number: 6140353Abstract: N-(4-carbamimidophenylamino) phenylglycineamide derivative compounds having the formula: ##STR1## in which E, g.sup.1, g.sup.2, Q, R and X.sup.1 to X.sup.4 are each as defined in the description, and hydrates or solvates and physiologically acceptable salts thereof can be used as inhibitors of the formation of the coagulation factors Xa, IXa and thrombin induced by the factor VIIa and by the tissue factor. These compounds can be used as medicaments for the treatment and/or prevention of thromboses, apoplexy, cardiac infarction, inflammation and arteriosclerosis or as antitumor agents.Type: GrantFiled: December 2, 1998Date of Patent: October 31, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Jean Ackermann, Katrin Grobke, Yu-Hua Ji, Sabine Wallbaum, Lutz Weber
-
Patent number: 6133315Abstract: Amidino and benzamidino compounds, including compounds of the formula: ##STR1## wherein R.sup.1 -R.sup.4, R.sup.6 -R.sup.9, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit a number of proteolytic enzymes are described. Also described are methods for preparing the compounds of Formula I.Type: GrantFiled: March 16, 1999Date of Patent: October 17, 2000Assignee: 3-Dimensional Pharmaceuticals, Inc.Inventors: Tianbao Lu, Bruce E. Tomczuk, Carl R. Illig, Richard M. Soll
-
Patent number: 6130251Abstract: The invention relates to new alkoximinoacetic acid amides, a process for their preparation and their use as agents for combating pests.Type: GrantFiled: July 23, 1997Date of Patent: October 10, 2000Assignee: Bayer AktiengesellschaftInventors: Thomas Seitz, Gerd Hanssler, Klaus Stenzel
-
Patent number: 6130315Abstract: This invention relates to analogs of peptidase substrates in which the amide group containing the scissile amide bond of the substrate peptide has been replaced by an activated electrophilic ketone moiety. These analogs of the peptidase substrates provide specific enzyme inhibitors for a variety of proteases, the inhibition of which will have useful physiological consequences in a variety of disease states.Type: GrantFiled: August 24, 1998Date of Patent: October 10, 2000Assignee: Merrell Pharmaceuticals Inc.Inventors: H. Michael Kolb, Joseph P. Burkhart, Michael J. Jung, Fritz E. Gerhart, deceased, Eugene L. Giroux, Bernhard Neises, Daniel G. Schirlin
-
Patent number: 6127341Abstract: Compounds of the general formula I ##STR1## compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone are described.Type: GrantFiled: June 1, 1998Date of Patent: October 3, 2000Assignee: Novo Nordisk A/SInventors: Thomas Kruse Hansen, Jesper Lau, Bernd Peschke, Michael Ankersen, Kjeld Madsen, Nils Langeland Johansen
-
Patent number: 6124277Abstract: This invention relates to peptide derivatives, pharmaceutical formulations containing those compound and methods of their use as thrombin inhibitors.Type: GrantFiled: March 11, 1999Date of Patent: September 26, 2000Assignee: Eli Lilly and CompanyInventors: Aaron L. Schacht, Gerald F. Smith, Michael R. Wiley
-
Patent number: 6114325Abstract: A 1,2-di-substituted benzene-carboxamide derivative or a salt thereof expressed by the following Formula (I); ##STR1## wherein each of A and B is R.sup.1 or --(CH.sub.2)n-NR.sup.2 R.sup.3, wherein when A is R.sup.1, B is --(CH.sub.2)n-NR.sup.2 R.sup.3 and when A is --(CH.sub.2)n-NR.sup.2 R.sup.3, B is R.sup.1 ; Z is --O--, --OCO--, --OCONR.sup.6 -- or --NR.sup.6 --; R.sup.1 is a hydrocarbon group of C.sub.10-30 ; R.sup.2 and R.sup.3 individually represent a hydrogen atom, a lower alkyl group, a phenyl group or a benzyl group, or together represent a heterocyclic ring having 3-7 members; when A is --(CH.sub.2)n-NR.sup.2 R.sup.3, R.sup.2 may be a hydrogen atom, a lower alkyl group, a phenyl group or a benzyl group, and R.sup.3 and R.sup.5 together may represent a heterocyclic ring of 6 or 7 members including two nitrogen atoms; when --Z--B is --OCONR.sup.6 --(CH.sub.2)n-NR.sup.2 R.sup.3 or --NR.sup.6 --(CH.sub.2)n-NR.sup.2 R.sup.3, R.sup.Type: GrantFiled: October 22, 1998Date of Patent: September 5, 2000Assignee: Shiseido Co., Ltd.Inventors: Hirotada Fukunishi, Kenichi Umishio, Masahiro Tajima, Koji Kobayashi
-
Patent number: 6114391Abstract: The present invention relates to serinamide, glycinamide, alaninamide and phenylalaninamide derivatives of formula (I) wherein R, R', R.sub.1 and R.sub.2 are as defined in the disclosure. The compounds (I) are useful for the treatment of neurological diseases.Type: GrantFiled: February 18, 1999Date of Patent: September 5, 2000Assignee: Chiesi Farmaceutici S.p.A.Inventors: Paolo Chiesi, Paolo Ventura, Maurizio Del Canale, Renato De Fanti, Elisabetta Armani, Gino Villetti, Claudio Pietra
-
Patent number: 6084130Abstract: Compounds and their pharmaceutically acceptable salts suitable for treating central nervous system disorders associated with the dopamine D3 receptor activity of structural Formula I: ##STR1##Type: GrantFiled: May 20, 1997Date of Patent: July 4, 2000Assignee: Pharmacia & Upjohn CompanyInventors: Arthur Glenn Romero, William Harold Darlington, Jeffrey A. Leiby, Chiu-Hong Lin, Susanne R. Haadsma-Svensson, Kerry Anne Cleek
-
Patent number: 6075055Abstract: A phenylalkane amide compound having the formula (1): ##STR1## wherein R.sup.1 -R.sup.4, X, n, Y, Z and Q are as defined herein. The compound is useful as an agricultural or horticultural fungicide.Type: GrantFiled: December 1, 1997Date of Patent: June 13, 2000Assignees: Kumiai Chemical Industry Co., Ltd., Ihara Chemical Industry Co., Ltd.Inventors: Katsumi Masuda, Ikumi Urushibata, Tsuyoshi Asahara, Katsumi Furuse, Yoshiyuki Kojima, Hiroshi Abe
-
Patent number: 6071957Abstract: The present invention relates to an antiandrogen compound and a method of treating prostate cancer in a patient utilizing the compound. The present invention also relates to a pharmaceutical composition which includes the compound.Type: GrantFiled: November 25, 1997Date of Patent: June 6, 2000Assignee: The University of Tennessee Research CorporationInventors: Duane D. Miller, Leonid I. Kirkovsky, James T. Dalton, Arnab Mukherjee
-
Patent number: 6066765Abstract: A group of benzamide compounds are disclosed which are useful for treating neurodegenerative disorders. Methods for making these compounds are provided. These materials are formed into pharmaceutical compositions for oral or intravenous administration to patients suffering from conditions such as Parkinson's disease which can exhibit themselves as progressive loss of central nervous system function. The compounds can arrest or slow the progressive loss of function.Type: GrantFiled: March 30, 1998Date of Patent: May 23, 2000Assignee: Centaur Pharmaceuticals, Inc.Inventors: William Flitter, William Garland, Richard Paylor, Allan Wilcox